Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Oral Bacteria May Cause Colorectal Cancer

By LabMedica International staff writers
Posted on 27 Aug 2013
Gut microbes have been linked to colorectal cancer, but it still unclear whether and how they might cause tumors to form in the first place. More...


Bacteria found in the mouth, known as Fusobacterium, stimulate poor immune responses, and turn on cancer growth genes to generate colorectal tumors; data, which could lead to more effective strategies for the early diagnosis, prevention, and treatment of colorectal cancer.

In recent studies, teams of scientists at the Dana-Farber Cancer Institute (Boston, MA, USA) found that Fusobacterium are prevalent in human adenomas, which are benign tumors that can become malignant over time, suggesting that these bacteria contribute to early stages of tumor formation. These bacteria accelerated the formation of tumors by attracting immune cells called myeloid cells, which invade tumors and stimulate inflammatory responses that can cause cancer.

In a separate study, scientists at the Case Western Reserve University (Cleveland, OH, USA) discovered that Fusobacterium nucleatum rely on a molecule called Fusobacterium adhesin A (FadA), which is found on the surface of these bacterial cells, to attach to and invade human colorectal cancer cells. FadA then turns on cancer growth genes, stimulates inflammatory responses in these cells, and promotes tumor formation. The FadA levels were much higher in tissues from patients with adenomas and colorectal cancer compared with healthy individuals. They also identified a compound that can prevent FadA's effects on cancer cells.

Wendy S. Garrett, MD, PhD, one of the senior authors, said, “Fusobacterium may provide not only a new way to group or describe colon cancers but also, more importantly, a new perspective on how to target pathways to halt tumor growth and spread." The authors concluded that unlike other bacteria linked to colorectal carcinoma, F. nucleatum does not exacerbate colitis, enteritis, or inflammation-associated intestinal carcinogenesis. However, their data suggest that, through recruitment of tumor-infiltrating immune cells, Fusobacterium generate a proinflammatory microenvironment that is conducive for colorectal neoplasia progression. The studies were published on August 14, 2013, in the journal Cell Host & Microbe.

Related Links:

Dana-Farber Cancer Institute
Case Western Reserve University



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.